Job ID: 103684

Research Associate in Circadian Biology – UK Dementia

Position: Post-doctoral Position

Deadline: 26 February 2023

City: London

Country: United Kingdom

Institution: Imperial College London



The Brancaccio Lab invites applications from talented, highly motivated and creative postdoctoral scientists to take a leading role in one of the following projects investigating molecular cellular and circuit mechanisms driving circadian dysfunction in pre-clinical models of Alzheimer’s disease (AD).

Project 1 Establishment of a platform for the validation of cellular chronotherapeutic targets for the prevention/delay Alzheimer’s pathology in brain tissue

In this project, you will develop an integrated platform for the identification of cell-type specific changes in circadian molecular pathways associated with early pathogenesis of Alzheimer’s disease. This platform will integrate cutting edge high throughput multiplexed live imaging in brain tissue, combinatorial intersectional genetics, and multivariate statistical analysis of time series to validate novel targets for chronotherapeutic interventions in Alzheimer’s disease. CRISPR/Cas9 and RNAi based experiments of functional interference will be used for the validation and manipulation of circadian pathways involved in disease. This is part of a major Imperial Medicine/ Michael Uren Foundation/ UK DRI initiative aimed to developing new translational avenues for the treatment and prevention of Alzheimer’s disease

Project 2 Investigating circadian dysfunction in hiPSC-derived glia-neuronal cultures isolated from Alzheimer’s disease patients 

In this project you will specific circadian signatures associated with Alzheimer’s disease, monitored in IPSCs derived cells isolated from Alzheimer’s disease patients and healthy subjects. The project will involve the generation and monitoring of cell-type specific reporters for high-throughput multiplexed live imaging of circadian function; time dependent gene expression profiling of circadian molecular pathways, and proof-of-principle designer chronotherapeutic glia interventions. This is a UK DRI/ ONO pharmaceutical collaborative project, aimed to validate glial manipulations for the prevention and therapy of Alzheimer’s disease in preclinical human models